Guardant360 CDx
Guardant Health, Inc. · Decision date Jan 15, 2026
What did the FDA approve?
FDA records P200010/S026 as a supplement to PMA P200010, with the supplement type “Panel Track”. The recorded decision is approval, dated Jan 15, 2026.
FDA approval order statement
Guardant360 CDx is a qualitative next generation sequencing-based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology for detection of single nucleotide variants (SNVs), insertions and deletions (indels) in 55 genes, copy number amplifications (CNAs) in two (2) genes, and fusions in four (4) genes. Guardant360 CDx utilizes circulating cell-free DNA (cfDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes (BCTs). The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with the therapies listed in Table 1 in accordance with the approved therapeutic product labeling.A negative result from a plasma specimen does not assure that the patients tumor is negative for genomic findings. Patients who are negative for the biomarkers listed in Table 1 should be reflexed to tissue biopsy testing for Table 1 biomarkers using an FDA-approved tumor tissue test, if feasible.*The efficacy of TAGRISSO (osimertinib) has not been established in the EGFR T790M plasma-positive, tissue-negative or unknown population and clinical data for T790M plasma-positive patients are limited; therefore, testing using plasma specimens is most appropriate for consideration in patients from whom a tumor biopsy cannot be obtained.Additionally, the test is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for cancer patients with any solid malignant neoplasm. The test is for use with patients previously diagnosed with cancer and in conjunction with other laboratory and clinical findings.Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.Guardant360 CDx is a single-site assay performed at Guardant Health, Inc.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Pathology
- Decision date
- Jan 15, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P200010/S026
- Regulatory pathway
- PMA supplement
- Applicant
- Guardant Health, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Jan 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Guardant Health, Inc.
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P200010. Subsequent supplements may change the device or its indications.
FDA decision timeline
P200010 · Original PMA
Guardant360 CDx
P200010/S026 received
Application receipt date recorded by FDA.
P200010/S021 · Related supplement
Guardant360 CDx
P200010/S028 · Related supplement
Guardant360 CDx
P200010/S026 · FDA decision
Panel Track
P200010/S025 · Related supplement
Guardant360 CDx
P200010/S027 · Related supplement
Guardant360 CDx
P200010/S031 · Related supplement
Guardant360 CDx
P200010/S030 · Related supplement
Guardant360 CDx
P200010/S032 · Related supplement
Guardant360 CDx
P200010/S024 · Related supplement
Guardant360 CDx
P200010/S029 · Related supplement
Guardant360 CDx
Timeline entries are records held by MedtechLedger for P200010. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200010
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Guardant360 CDxP200010 | Guardant Health, Inc. | PMA approval | Aug 7, 2020 | FDA |
Guardant360 CDxP200010/S021 | Guardant Health, Inc. | PMA supplement | Sep 25, 2025 | FDA |
Guardant360 CDxP200010/S028 | Guardant Health, Inc. | PMA supplement | Dec 29, 2025 | FDA |
Guardant360 CDxP200010/S025 | Guardant Health, Inc. | PMA supplement | May 1, 2026 | FDA |
Guardant360 CDxP200010/S027 | Guardant Health, Inc. | PMA supplement | Jun 10, 2026 | FDA |
Guardant360 CDxP200010/S031 | Guardant Health, Inc. | PMA supplement | Jul 6, 2026 | FDA |
Guardant360 CDxP200010/S030 | Guardant Health, Inc. | PMA supplement | Jul 14, 2026 | FDA |
Guardant360 CDxP200010/S032 | Guardant Health, Inc. | PMA supplement | Aug 7, 2026 | FDA |
Guardant360 CDxP200010/S024 | Guardant Health, Inc. | PMA supplement | Sep 4, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Guardant Health, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 505 Penobscot Dr., Redwood City, CA, 94063
Sources and methodology
- Original FDA record: P200010/S026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




